XML 83 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Apr. 04, 2021
Mar. 29, 2020
EPS Numerator––Basic    
Income from continuing operations attributable to Pfizer Inc. $ 4,868 $ 2,474
Less: Preferred stock dividends––net of tax 0 0
Income from continuing operations attributable to Pfizer Inc. common shareholders 4,868 2,474
Income from discontinued operations––net of tax 9 881
Net income attributable to Pfizer Inc. common shareholders 4,877 3,354
EPS Numerator––Diluted    
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions 4,868 2,474
Income from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 9 881
Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 4,877 $ 3,355
EPS Denominator    
Weighted-average number of common shares outstanding––Basic 5,584 5,545
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares) 78 68
Weighted-average number of common shares outstanding––Diluted (shares) 5,662 5,613
Anti-dilutive common stock equivalents (shares) [1] 2 3
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.